search
Back to results

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety ([11C]Butanol)

Primary Purpose

Neuro-Degenerative Disease

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Carbon 11 Butanol
Sponsored by
Weill Medical College of Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Neuro-Degenerative Disease

Eligibility Criteria

18 Years - 89 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • able to give informed consent.
  • age 18-89
  • Subjectively healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures and be compliant with the schedule of follow up telephone calls.
  • Normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute while sitting. At the discretion of the investigators, people who regularly engage in vigorous exercise more than four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting.
  • Unremarkable electrocardiograms, with PR intervals of less than 200 mSec and QTcF intervals (corrected with Frederica's method) of less than 440 mSec.
  • No concurrent medications with the exception of p.r.n. NSAIDS, which must be discontinued one week prior to PET scanning.
  • Willing and able to refrain from abusing any recreational drugs, including marijuana, and drink less than one unit of alcoholic beverages per day starting one week prior to PET scanning, and avoided for the next four weeks.
  • Willing to refrain from donating blood for four (4) weeks before the study and for four (4) weeks after the study.
  • Willing to refrain from participating in any other research study that requires taking medication for four (4) weeks before the study and for four (4) weeks after the study.
  • Willing to refrain from being vaccinated for four (4) weeks before the study and for four (4) weeks after the study.
  • All clinical laboratory test results within normal limits or not clinically significant. For example, elevated bilirubin levels in subjects with Gilbert's syndrome will be allowed, as will small red blood cell volumes in healthy people with sickle cell trait.

Exclusion Criteria:

  • Subjects may not be a member of a vulnerable population.
  • Women may not be pregnant or breast feeding.
  • History of multiple hypersensitivity reactions (atopia), as indicated by allergies to multiple medications, foods, and seasonal pollens.
  • History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination (ADME) of the tracer, including chronic liver or renal failure.
  • Positive urine toxicology screen for recreational drugs other than marijuana.
  • May not have taken any controlled medications, including other study drugs, in the 30 days prior to PET scanning or for 10 half-lives, whichever is longer.
  • May not have donated blood in the 30 days prior to PET scanning.
  • May not have participated in research administering drugs in the last 30 days.
  • May not have been vaccinated in the 30 days prior to PET scanning.
  • May not have been exposed to radiation during research of more than 10 mSv during the last year.

Sites / Locations

  • Weill Cornell Medicine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Healthy Controls

Arm Description

Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.

Outcomes

Primary Outcome Measures

Effective Dose (ED)
Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling).

Secondary Outcome Measures

Change in Radiochemical Safety Assessments
Change in pulse
Change in Radiochemical Safety Assessments
Change in blood pressure
Change in Radiochemical Safety Assessments
Change in heart rhythm on electrocardiogram (ECG)
Change in number of Subjects with prolonged PR interval greater than 20 mSec
Change in PR interval on electrocardiogram (ECG)
Change in number of subjects with QTc >440 mSec
Change in corrected QT interval on electrocardiogram (ECG).

Full Information

First Posted
August 6, 2019
Last Updated
June 16, 2021
Sponsor
Weill Medical College of Cornell University
search

1. Study Identification

Unique Protocol Identification Number
NCT04050800
Brief Title
Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety
Acronym
[11C]Butanol
Official Title
Characterizing the Safety of [Carbon-11]Butanol and Estimating the Test-Retest Variance in Measurements of Its Whole Body Biokinetics Under Zero-Biological-Change Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
September 17, 2020 (Actual)
Primary Completion Date
December 29, 2020 (Actual)
Study Completion Date
January 5, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.
Detailed Description
Vital signs (VSs) will be measured, electrocardiograms (ECGs) will be acquired, and blood will be sent to the clinical laboratory for safety assessments before a single dose, intravenous (IV) administration of 555 MBq of Carbon-11 butanol. VSs will be re-measured, ECGs will be acquired again, and more blood will be sent to the clinical laboratory for repeat safety assessments after 2 hours of whole body (WB) scanning. WB scanning will consist of imaging acquisition sweeps of 200 cm from head-to-toe over 180 secs (3 min). Up to 40 sweeps per imaging session will be performed. The subjects will then be given a rest period ("coffee break") for about two hours, after which the entire sequence of events will be repeated. The primary outcome measure will be related to radiation safety derived from the areas under the time-activity curves (AUCs) for internal organs. Co-primary clinical safety measures will include changes in VSs, ECG parameters such as the PR and corrected QT intervals, and clinical laboratory tests, such as proteins that reflect renal and hepatic function. Secondary endpoints will include the time-activity curves (TACs) and total volumes of distribution (VT) in several brain regions. The results should allow calculation of the repeatability coefficients (RCs) under zero-biological-change conditions. RC values will be essential for understanding whether future measurements of effect sizes in response to therapeutic maneuvers or the differences between groups are meaningful.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuro-Degenerative Disease

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy Controls
Arm Type
Experimental
Arm Description
Subjects will be administered two sequential doses of the radiopharmaceutical under nearly zero-biological-change conditions.
Intervention Type
Drug
Intervention Name(s)
Carbon 11 Butanol
Other Intervention Name(s)
[11C]Butan-1-Ol
Intervention Description
Two sequential administrations of a PET tracer
Primary Outcome Measure Information:
Title
Effective Dose (ED)
Description
Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling).
Time Frame
Day 1, from the measurements of exposures during the first 2 hours post administration.
Secondary Outcome Measure Information:
Title
Change in Radiochemical Safety Assessments
Description
Change in pulse
Time Frame
Pulse at two hours post administration compared to pulse shortly before administration.
Title
Change in Radiochemical Safety Assessments
Description
Change in blood pressure
Time Frame
Blood pressure at two hours post administration compared to blood pressure shortly before administration.
Title
Change in Radiochemical Safety Assessments
Description
Change in heart rhythm on electrocardiogram (ECG)
Time Frame
At two hours post administration compared to same parameters shortly before administration.
Title
Change in number of Subjects with prolonged PR interval greater than 20 mSec
Description
Change in PR interval on electrocardiogram (ECG)
Time Frame
At two hours post administration compared to same parameters shortly before administration.
Title
Change in number of subjects with QTc >440 mSec
Description
Change in corrected QT interval on electrocardiogram (ECG).
Time Frame
At two hours post administration compared to same parameters shortly before administration.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: able to give informed consent. age 18-89 Subjectively healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures and be compliant with the schedule of follow up telephone calls. Normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute while sitting. At the discretion of the investigators, people who regularly engage in vigorous exercise more than four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting. Unremarkable electrocardiograms, with PR intervals of less than 200 mSec and QTcF intervals (corrected with Frederica's method) of less than 440 mSec. No concurrent medications with the exception of p.r.n. NSAIDS, which must be discontinued one week prior to PET scanning. Willing and able to refrain from abusing any recreational drugs, including marijuana, and drink less than one unit of alcoholic beverages per day starting one week prior to PET scanning, and avoided for the next four weeks. Willing to refrain from donating blood for four (4) weeks before the study and for four (4) weeks after the study. Willing to refrain from participating in any other research study that requires taking medication for four (4) weeks before the study and for four (4) weeks after the study. Willing to refrain from being vaccinated for four (4) weeks before the study and for four (4) weeks after the study. All clinical laboratory test results within normal limits or not clinically significant. For example, elevated bilirubin levels in subjects with Gilbert's syndrome will be allowed, as will small red blood cell volumes in healthy people with sickle cell trait. Exclusion Criteria: Subjects may not be a member of a vulnerable population. Women may not be pregnant or breast feeding. History of multiple hypersensitivity reactions (atopia), as indicated by allergies to multiple medications, foods, and seasonal pollens. History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination (ADME) of the tracer, including chronic liver or renal failure. Positive urine toxicology screen for recreational drugs other than marijuana. May not have taken any controlled medications, including other study drugs, in the 30 days prior to PET scanning or for 10 half-lives, whichever is longer. May not have donated blood in the 30 days prior to PET scanning. May not have participated in research administering drugs in the last 30 days. May not have been vaccinated in the 30 days prior to PET scanning. May not have been exposed to radiation during research of more than 10 mSv during the last year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
P. David Mozley, MD
Organizational Affiliation
Cornell University Weill College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All de-identified data will be shared. The investigators will attempt to contribute the "raw" imaging data to a public archive for curation.
IPD Sharing Time Frame
Upon publication of the results.
IPD Sharing Access Criteria
Any investigators with a reasonable request for the data.

Learn more about this trial

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety

We'll reach out to this number within 24 hrs